Lab Reagents
Human IgG antibody Laboratories manufactures the sakura tissue tek ca reagents distributed by Genprice. The Sakura Tissue Tek Ca reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact sakura tissue tek. Other Sakura products are available in stock. Specificity: Sakura Category: Tissue Group: Tek Ca
Tek Ca information
Anti-TEK antibody |
|
STJ29302 |
St John's Laboratory |
100 µl |
EUR 332.4 |
|
Description: This gene encodes a receptor that belongs to the protein tyrosine kinase Tie2 family. The encoded protein possesses a unique extracellular region that contains two immunoglobulin-like domains, three epidermal growth factor (EGF)-like domains and three fibronectin type III repeats. The ligand angiopoietin-1 binds to this receptor and mediates a signaling pathway that functions in embryonic vascular development. Mutations in this gene are associated with inherited venous malformations of the skin and mucous membranes. Alternative splicing results in multiple transcript variants. Additional alternatively spliced transcript variants of this gene have been described, but their full-length nature is not known. |
AN3 CA |
|
C0026002 |
Addexbio |
One Frozen vial |
EUR 651.6 |
CA 074 |
|
A1926-1 |
ApexBio |
1 mg |
EUR 177.6 |
|
Description: CA-074, a specific cathepsin B inhibitor, also abolished the neurotoxic effects caused by Abeta42-activated BV2 cell [1]. Co-treatment of cultures with the cathepsin B inhibitors CA-074 or Z-FA-FMK suppressed the cytostatic effects of TPA and activation of pro-uPA [2]. |
CA 074 |
|
A1926-10 |
ApexBio |
10 mg |
EUR 582 |
|
Description: CA-074, a specific cathepsin B inhibitor, also abolished the neurotoxic effects caused by Abeta42-activated BV2 cell [1]. Co-treatment of cultures with the cathepsin B inhibitors CA-074 or Z-FA-FMK suppressed the cytostatic effects of TPA and activation of pro-uPA [2]. |
CA 074 |
|
A1926-25 |
ApexBio |
25 mg |
EUR 895.2 |
|
Description: CA-074, a specific cathepsin B inhibitor, also abolished the neurotoxic effects caused by Abeta42-activated BV2 cell [1]. Co-treatment of cultures with the cathepsin B inhibitors CA-074 or Z-FA-FMK suppressed the cytostatic effects of TPA and activation of pro-uPA [2]. |
CA 074 |
|
A1926-5 |
ApexBio |
5 mg |
EUR 373.2 |
|
Description: CA-074, a specific cathepsin B inhibitor, also abolished the neurotoxic effects caused by Abeta42-activated BV2 cell [1]. Co-treatment of cultures with the cathepsin B inhibitors CA-074 or Z-FA-FMK suppressed the cytostatic effects of TPA and activation of pro-uPA [2]. |
CA 074 |
|
A1926-5.1 |
ApexBio |
10 mM (in 1mL DMSO) |
EUR 518.4 |
|
Description: CA-074, a specific cathepsin B inhibitor, also abolished the neurotoxic effects caused by Abeta42-activated BV2 cell [1]. Co-treatment of cultures with the cathepsin B inhibitors CA-074 or Z-FA-FMK suppressed the cytostatic effects of TPA and activation of pro-uPA [2]. |
CA 074 |
|
A1926-S |
ApexBio |
Evaluation Sample |
EUR 97.2 |
|
Description: CA-074, a specific cathepsin B inhibitor, also abolished the neurotoxic effects caused by Abeta42-activated BV2 cell [1]. Co-treatment of cultures with the cathepsin B inhibitors CA-074 or Z-FA-FMK suppressed the cytostatic effects of TPA and activation of pro-uPA [2]. |
